# Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis

> **NCT01460836** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Tobramycin solution for inhalation
- **DRUG:** Aztreonam lysine for inhalation

## Key facts

- **NCT ID:** NCT01460836
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-10
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2011-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01460836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01460836, "Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01460836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*